Home › Research › Inflammation and the immune system
Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update
Asem Surindro Singh, Afsar Raza Naqvi, Machathoibi Takhellambam Chanu. Innovative Medicines & Omics, 2025-03-28
Topic: Amyloid, tau and blood-test diagnosis
According to the latest report in 2024 by the World Health Organization, based on global data from 2021, Alzheimer’s disease (AD) and other forms of dementia rank seventh among the leading causes of death worldwide, with an estimated 1.8 million deaths. This alarming number underscores the urgent requirement for effective treatments. AD and other dementias also severely affect the global economy. Unfortunately, no cure has been found, and effective treatments remain limited. Over the past two decades, thousands of disease-modifying drugs have been developed for AD treatment. However, most have failed to progress beyond phase I clinical trials, with only a few reaching phase III. To date, lecanemab (sold under the brand name Leqembi) is the only drug to receive full approval from the United States Food and Drug Administration for slowing AD progression. This drug is specifically designed to target and clear amyloid-beta (Aβ) plaques. Apart from targeting Aβ aggregation and tau tangles, neuroinflammatory regulatory pathways have emerged as promising therapeutic targets. With advancing research, neuroinflammation has been considered one of the core characteristics of AD and the third major pathological hallmark of the disease after Aβ plaques and neurofibrillary tau tangles. In this review, we summarize key research findings in neuroinflammatory regulation of AD and related dementias that are promising for treatments. We also provide an overview of clinical trials targeting the immune system or neuroinflammatory regulatory pathways, analyzing their challenges and potential successes.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2025). Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update. Innovative Medicines & Omics. https://doi.org/10.36922/imo025050007
Vancouver
Singh AS, Naqvi AR, Chanu MT. Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update. Innovative Medicines & Omics. 2025. doi:10.36922/imo025050007.
BibTeX
@article{singh2025-1ee39399,
author = {Singh, Asem Surindro and Naqvi, Afsar Raza and Chanu, Machathoibi Takhellambam},
title = {{Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update}},
journal = {Innovative Medicines \& Omics},
year = {2025},
doi = {10.36922/imo025050007},
url = {https://doi.org/10.36922/imo025050007}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This drug is specifically designed to target and clear amyloid-beta (Aβ) plaques.
- Apart from targeting Aβ aggregation and tau tangles, neuroinflammatory regulatory pathways have emerged as promising therapeutic targets.
- With advancing research, neuroinflammation has been considered one of the core characteristics of AD and the third major pathological hallmark of the disease after Aβ plaques and neurofibrillary tau tangles.
- In this review, we summarize key research findings in neuroinflammatory regulation of AD and related dementias that are promising for treatments.
- We also provide an overview of clinical trials targeting the immune system or neuroinflammatory regulatory pathways, analyzing their challenges and potential successes.
Why it matters
This review notes that no cure exists and effective treatments remain limited, with lecanemab the only fully approved drug for slowing Alzheimer's progression by clearing amyloid-beta plaques. It highlights neuroinflammatory pathways as promising targets, but these are not yet proven treatments.
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 31 of the 97 points we could judge it on, which is 32 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Innovative Medicines & Omics) |
| Journal's citation record | 0 / 4 | Innovative Medicines & Omics: journal h-index 3 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Machathoibi Takhellambam Chanu: h-index 4 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 31 of the 97 points we could judge it on is 32 out of 100. |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Inflammation and the immune system
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.